Albert David Limited has informed the Exchange regarding Board meeting held on May 13, 2025. i.e Approval of Audited Financial Results for quarter and year ended 31st March, 2025.
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.9 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited reported audited results for Q4 and FY ended March 31, 2025 with a clean (unmodified) audit opinion from L. B. Jha & Co. Full-year revenue from operations fell about 4.6% to Rs. 34,576.80 lakhs from Rs. 36,246.17 lakhs a year ago, while profit after tax crashed roughly 77% to Rs. 1,720.08 lakhs from Rs. 7,542.01 lakhs. Q4 alone slipped into a loss of Rs. 1,032.79 lakhs versus a profit of Rs. 1,291.26 lakhs in the year-ago quarter, mainly due to a sharp swing in other income. Operating cash flow turned sharply negative at Rs. (2,843.58) lakhs versus an inflow of Rs. 4,550.22 lakhs last year. The board recommended a final dividend of Rs. 5 per share (50% on face value), with July 25, 2025 set as the record date, and reappointed/appointed internal, secretarial, and cost auditors for FY26 onwards.
Shareholders get a steady 50% dividend despite sharply weaker earnings, but the steep fall in profits and a large negative operating cash flow are red flags that could weigh on the stock. Investors should watch for clarity on why other income turned negative and why working capital absorbed so much cash, as these drove the FY25 underperformance.